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Summary: The following serum analytes were measured in 464 patients with defined carcinomas and other
tumours as well as those with chronic obstructive lung disease and under regular haemodialysis, and in 261
healthy controls: thyrotropin (TSH), thyroxine (T4), triiodothyronine (T3), free thyroxine (fT4), thyroxine
binding globulin (TBG) and transthyretin (TTR).
The following ratios were constructed:
fT4 χ TTR, defined as the thyroxine availability index
fT4/TTR, defined as the thyroid hormone compensation index
100 χ T3/TBG as the free T3 index (fT3I) and
ΓΓ3Ι χ TTR, defined as the triiodothyronine availability index.
Significantly elevated thyrotropin values (p = 0.05) were only found in patients with breast cancer when
compared with age matched controls, although elevated T4 and fT4 values were found in all experimental
groups except the haemodialysis patients (p < 0.01). The thyroxine availability index and triiodothyronine
availability index values were not significantly different from the age matched controls (> 60 a) in the cancer
groups, showing that the transthyretin concentrations compensated for changes in fT4 or vice versa. These
findings are reflected in the euthyroid thyrotropin values. The T4 and fT4 values in the dialysis patient group
were significantly lower than in the age matched controls (p < 0.01), while the transthyretin values were
significantly higher (p < 0.01), which accounted for the normal thyroxine availability index and euthyroid
thyrotropin values.
Introduction
τ^ ·* *u <· * *t * * Λ +· /ττ··η\ u u hormones into the cell, a property which would makeDespite the fact that transthyretin (TTR) has been x , . . ^ ^ : t, Γ . " * * *Λ -J1. transthyretin a n active partner m thyroid hormoneknown for many years to transport thyroid hormones .. .:.. J
(1) it has never been used as a routine thyroid function
parameter. Newer investigations of the actions of thyroid hor-
T A ^ , , , . . . . . - mones at the cellular level by Oppenheimer et al. (9)Interest has been shown in its association with nutn- « t , Γ,^ ^Λ^ΛΛ j
f · n · · j · · have also mentioned a receptor of Afr = 50 500 and ational states, especially in patients under intensive care - ΛΛΛ . -Γ , , ,. Γ « · u,* ,·% j · ιΓ /^ Γ™ · · · protein of Μτ = 56 000 in the nucleus, both of which(2—4) and with cancer (5). The main interest in trans- f. - _ / ru\ . . 1 . 1 . · · * · *· bind T3. Although the relative molecular mass of boththyretm in recent years has been in its association . . -/, r .-. . ι - j · /^ ^ proteins was similar to that reported for transthyretinwith familial amyloidosis (6,7). ,. CCAAA /(ΙΛλ , . .,J v ' y Mr = 55000 (10), there is no evidence to connect
Abdukarimov (8) showed that transthyretin is able to transthyretin with these proteins which are structur-
permeate the cell membrane and transport thyroid ally dissimilar (11, 12).
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There are many diseased states where thyrotropin
concentrations are normal, but where other thyroid
parameters are pathological.
The aim of this article was to investigate the role of
transthyretin in chronically sick patients and how it
relates to conventional thyroid hormone parameters
such as thyrotropin, thyroxine binding globulin
(TBG), T4, T3 and fT4.
As there are three possible mechanisms by which T3
and T4 can enter the cell (receptor-mediation, diffu-
sion as fT4 and fT3 or, if Abdukarimov is correct,
coupled to transthyretin (TTR)), the following quo-
tients were constructed:
a. fT4 χ TTR — defined as the thyroxine availability
index
b. fT4/TTR — defined as the thyroxine compensation
index
c. fT3I χ TTR — defined as the triiodothyronine
availability index
The thyroxine availability index and to a lesser extent,
the triiodothyronine availability index represent the
potential transport capacity of thyroid hormones into
the cell via the two routes described above.
The thyroxine compensation index reflects the inverse
behaviour of both transport systems.
A triiodothyronine compensation index was not cal-
culated, as the peripheral conversion of T4 to T3
occurs mainly in the cell via the 5'-deiodinase (13).
Human liver is also a potent source of S'-deiodinase,
but reverse triiodothyronine (rT3) is the preferred
substrate (14).
In addition, the T3/TBG quotient was used to calcu-
late an fT3 index (fT3I). A total of 725 individuals
was studied over a three-year period, the main results
of which are summarised in this publication.
Materials and Methods
Control groups
As the concentration of many thyroid parameters in blood is
age-dependent, the concentrations of analytes were also meas-
ured in three control groups with normal thyroid function.
Persons taking oral contraceptives were excluded, as were those
with positive antibody titers to microsomal peroxidase and
thyroglobulin. All persons were healthy in terms of subjective
wellbeing, and had normal aminotransferase, γ-glutamyltrans-
ferase, serum creatinine and blood smear.
Group 1 consisted of adults under 40 (n = 115),
group 2 of persons between 40 and 60 (n = 116) and
group 3 of persons over 60 years of age (n = 30).
The "over-60" group was used as an aged-matched control for
the sick groups, as the age ranges of these groups did not differ
significantly. The reason for the 3 control groups was to confirm
that the analyte concentrations found in normal euthyroid
persons were comparable with those already published by other
workers.
As the results from the two younger control groups were not
used for further comparison, sex-linked hormone differences in
women of child-bearing age were not taken into account.
The "over-60" group consisted of active individuals in a rural
area, who were healthy except for a few cases of partial deafness.
Exper imenta l groups
These consisted of defined cancer patients, which were grouped
as follows:
Various carcinomata (n = 59),
other malignant tumour-bearers without carcinomata (n = 43),
breast cancer (n = 45),
gastrointestinal cancer (n = 63),
lung cancer (n = 50) and
ovarian cancer (n = 43).
The group of patients with various carcinomata included cases
of cancer of the cervix, uterus, vagina, head and neck, oeso-
phagus, gall bladder, pancreas and a primary hepatoma. The
tumour group consisted of patients with lymphoma, Hodgkirfs
disease, leukaemia (acute lymphatic (ALL), acute myeloic
(AML), chronic lymphatic (CLL), chronic myeloic (CML)),
melanoma, sarcoma and teratoma. Fifty three patients with
chronic obstructive lung disease who had no malignant disease
were included in the study, as were 58 patients under haemo-
dialysis, as these groups represented patients with metabolic
and respiratory acidosis and dysproteinaemia.
In addition, 58 patients suffering from hypo- and hyperthy-
roidism, who attended to thyroid outpatient clinic, were ex-
amined either before, or during treatment, the criterion for
inclusion in this study being an abnormal thyrotropin value on
the first admission to the outpatient clinic. These patients were
examined in the initial phase of treatment — i.e. before the
thyrotropin concentrations returned to normal.
Methods
The following methods were used to determine the concentra-
tions of the parameters measured in this study.
In-house immunoluminometric assays were used to measure
thyrotropin, thyroxine binding globulin and transthyretin, and
they have been published in detail elsewhere (15 — 17). T3 was
measured with a luminescence enhanced enzyme immunoassay
(Amerlite —Amersham-Buchler, Braunschweig, FRG.).
T4 and fT4 were measured with the SPAC-ET radioimmunoas-
say (Byk-Sangtec, Dietzenbach, FRG.) using an indirect cal-
culation (two-tube method) for the estimation of free thyroxine.
Stat is t ics
Non-parametric statistics were used throughout as the data
were not normally distributed. The Mann- Whitney U-test with
z-transformation was used for independent data pairs. Median
values and relevant percentiles are used throughout. Signifi-
cance levels were given at the 5% and 1% levels (p ̂  0.05 or
0.01). For testing the variances of the three reference collectives,
the Kruskal- Wallis test was applied.
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Tab. 1. Laboratory internal reference ranges for the parameters
measured in this publication. All values are for adults






































Key: 1 — Thyroxine availability index
2 — Thyroxine compensation index
3 - Triiodothyronine availability index
4 - Free triiodothyronine index
These abbreviations are used in the subsequent tables
Tab. 2. Median values for the control groups together with
significance levels, where relevant.
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Table 1 shows the laboratory internal reference ranges
for healthy individuals for. the parameters measured.
These are for adults aged 18 — 65 and have been
established over long periods for the methods de-
scribed here.
Table 2 shows the median values of the measured
parameters in the three control groups, as well as the
values for the constructed quotients. The median ages
of the groups were 24, 46 and 63 years respectively.
Experimental group values
Table 3 shows the distribution of results for the dif-
ferent groups. The median ages of the groups lay
between 59 and 69 years. Figures l a — I f show the
data from the 58 hyper- and hypothyroid patients
and show especially the interesting behaviour of the
thyroxine availability index in the treated hypothyroid
patients. The data is presented visually in the form of
box and whisker diagrams (18). In hyperthyroid pa-
tients, the fT4, triiodothyronine and thyroxine avail-
ability indices decreased significantly (p < 0.01) dur-
ing treatment. Hypothyroid patients showed signifi-
cant increases in the fT4, fT3I, transthyretin, thyroxine
and triiodothyronine availability indices. Thyrotropin
concentrations in the hyperthyroid groups were all
non-detectable (< 0.03 mU/1). Median thyrotropin
levels were 35 mU/1 in the untreated hypothyroid
patients, and 18 mU/1 under treatment.
Thyrotropin values were significantly higher in the
breast cancer group, which agrees with published data
(19). Many of the women in this group were under
hormone therapy, the nature of which was dependent
upon whether the tumour was oestrogen receptor-
positive or not. Individual therapy was not controlled,
as this was not part of the study.
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Group: 1 2 3 4
Median: 0.28 0.15 0.17 0.46
1 2 3 4
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3.36 1.51 0.45 3.40
M
1 2 3 4
11.20 2.52 0.90 3.88
Fig. la —If . Box and whisker diagrams for the distribution of the data from 58 untreated and treated hyper- and hypothyroid
patients with abnormal serum thyrotropin values.
1. hyperthyroid patients — untreated (n = 13)
2. hyperthyroid patients — under treatment (n = 19)
3. hypothyroid patients — untreated (n = 13)
4. hypothyroid patients — under treatment (n = 13)
Individual values are shown beside each box and whisker diagram. The median values for each group are shown in
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FT4 was significantly higher in all cancer groups and
in the chronic obstructive lung disease group. It was
significantly lower in the dialysis patients.
Transthyretin concentrations were significantly lower
in the breast cancer and lung cancer groups. They
were significantly higher in the dialysis patients.
Thyroxine binding globulin and T4 levels were signif-
icantly higher in all groups except the dialysis patients,
where significantly lower values were found.
T3 levels were significantly higher in all groups except
the chronic obstructive lung disease patients, where
they were significantly lower. The free triiodothyron-
ine index (fT3I) was significantly lower in the tumour
groups.
The triiodothyronine availability index values were
significantly lower in the tumour, gastrointestinal,
breast and lung cancer groups, and significantly
higher in the dialysis patients.
The triiodothyronine availability index behaved dif-
ferently from the thyroxine availability index, which
may be associated with the peripheral deiodination of
T4.
The thyroxine compensation index was significantly
higher in all the cancer groups, and it was significantly
lower in the dialysis group. The thyroxine availability
index was not significantly different from the "over-
60" control group. In the control groups there was
no significant correlation between the transthyretin
and fT4 values, which shows the independence of both
thyroid hormone transport pathways under healthy
conditions.
Discussion
Thyroid status in chronic disease and cases of dys-
proteinaemia has been discussed for over two decades.
Critical observations have been made on hyperthy-
roidism in elderly chronically ill patients, and large
fluctuations in thyroid hormone levels in individual
patients have been reported (20). The question has
been raised as to whether secondary hypothyroidism
is present in severe non-thyroidal illness, in view of a
blunted thyrotropin response and low T4 levels in
severely ill patients (21),
In a comprehensive review on the "euthyroid sick
syndrome" Wartofsky & Burman (22) came to the
conclusion that despite abnormal single thyroid hor-
mone parameters, most sick patients without manifest
thyroid disease were euthyroid, based on the serum
thyrotropin value as the indicator of thyroid status.
An increased incidence of low T3 levels in lung cancer
cases has been described (23) as well as increased
thyrotropin levels in lymphoma patients undergoing
radiation treatment (24), although this could not be
confirmed in the tumour group in the present study
which also contained such patients.
The lower thyroid hormone levels in patients with
chronic renal failure is well documented (25) and these
findings are augmented by the findings of the present
study. The variation of transthyretin levels in disease
is less well known; Kirby et al. (26) reported that
transthyretin synthesis is reduced during "surgery of
moderate severity" and that this had an effect on
thyroid function in such patients.
The rise in transthyretin values under nutritional ther-
apy has been published for undernourished neonates
and infants (3, 4), as well as in chronically ill patients
(2), where transthyretin and retinol binding protein ·
were the best indices of malnutrition.
The fall in transthyretin and thyroxine binding glob-
ulin in elderly people, even when these lead an active
life, as was the case of the "over-60" control group,
may reflect a lowering of the metabolic rate combined
with a nutritional component. This is supported by
the fall in the thyroxine availability index in healthy
individuals with increasing age. Perhaps this is related
to the process of aging itself or it may be the result
of other factors. If the serum thyrotropin level is taken
as the index of thyroid status, then 33 of the 423
patients in the experimental groups (excluding the 58
patients with known hyper- and hypothyroidism) had
a level of under 0.2 mU/1 and could be described as
primary hyperthyroid or secondary hypothyroid.
Three patients had a thyrotropin of above 5 mU/1
and could be classed as primary hypothyroid or sec-
ondary hyperthyroid. In terms of percentages the
figures are 7.8% and 0.71% for low and high thyro-
tropin respectively, and they agree with the frequency
found in other reports (22).
The thyroxine availability index allows the potential
thyroid hormone availability at the cellular level to
be determined. In dysproteinaemia, which is found in
the majority of dialysis patients, the high circulating
transthyreotin levels are compensated for by a reduc-
tion of the free thyroid hormone concentrations, as
shown in table 3. The triiodothyronine availability
index did not appear to play as important a role as
the thyroxine availability index, although intracellular
deiodination of T4 to T3 may "bypass" any effect seen
in this index.
Similarly, in cases of reduced transthyretin concentra-
tions, as is often the case in chronic illness, the free
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thyroid hormone fraction is elevated, as reflected in
the thyroxine compensation index. The importance of
transthyretin can be seen in the hyper- and hypo-
thyroid patient groups. Where excessively high free
thyroid hormones were measured it was often seen
that the transthyretin levels were reduced to subnor-
mal values, although this was not always the case. In
contrast, the treatment of overt hypothyroid patients
with thyroxine led to an increase in transthyretin
synthesis (fig. la) in the phase where pituitary regu-
lation was still abnormal (thyrotropin still elevated,
despite normalised thyroid hormone values), this may
be explained as a response at the cellular level to
maximise the inflow of available thyroid hormones in
the phase of increased energy demand. Figure 1 sup-
ports the claim that the thyroxine availability index
reflects thyroid status (figs, la, Id) and can be used
in monitoring the efficacy of thyroid treatment (figs,
le, If). Similar findings have been described by Ishida
et al. (27), who noticed that transthyretin levels did
not return to normal in treated hypo- and hyperthy-
roid patients until a euthyroid state was attained.
It must be born in mind that transthyretin not only
transports thyroid hormones, but also other hor-
mones and substances such as thymulin (28) and
vitamin A in complex with retinol binding protein
(11). Transthyretin may serve as a detoxification
mechanism for dioxins (29) and beryllium (30). The
multifunction of transthyretin must be taken into
account when trying to complete the picture in cases
of transthyretin deficiency.
To summarise, the value of transthyretin in helping
to explain thyroid function at a cellular level has been
demonstrated, especially when combined with the free
thyroid hormone levels. The thyroxine availability
index reflects the metabolic capacity at cellular levels,
and should be included as part of a routine investi-
gation of thyroid status in chronic illness.
The expected thyrotropin response is seen only when
the thyroxine availability index moves out of the
euthyroid range. In the present study, this was not
the case in the cancer and dialysis groups, as the
thyroxine availability index, despite abnormal fT4 val-
ues in certain groups, was normal due to compensa-
tory transthyretin concentration changes.
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